# New ADAI Research: Cannabis-Related Problems and Clinical Experiences

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/cannabis-use-disorder-clinical-education-insights/
> **Published:** 2026-03-31T03:02:21-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:34:23-04:00
> **Clinical Summary:** Explore new ADAI research on cannabis use disorder clinical education and provider training to improve healthcare interventions and patient care.

---

✦ New
CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely.
⚒ Cannabis News  |  CED Clinic
Provider Training[Cannabis Use Disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/)Clinical EducationHealthcare SystemsSubstance Abuse

Why This Matters

Healthcare providers consistently report feeling unprepared to address cannabis-related problems, creating gaps in [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) and missed opportunities for early intervention. This Washington State research highlights the disconnect between cannabis prevalence in clinical practice and provider confidence in managing cannabis-related issues.

Clinical Summary
The ADAI study surveyed healthcare providers across Washington State regarding their experiences with cannabis-related problems and barriers to clinical intervention. Findings reveal that while providers frequently encounter patients with [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) concerns, many lack the training, resources, and institutional support needed to effectively assess and address these issues. The research identifies specific knowledge gaps and systemic barriers that prevent optimal cannabis-related care delivery.

Dr. Caplan’s Take

“This mirrors what I see nationally—clinicians want to help patients navigate [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) safely, but medical education hasn’t caught up to clinical reality. The solution isn’t avoiding the conversation; it’s building competency through targeted training and evidence-based protocols.”

Clinical Perspective
🧠 Providers should recognize that basic cannabis screening and motivational interviewing skills can be developed and applied immediately. Consider establishing clear referral pathways for complex cannabis use disorders, and advocate for institutional [cannabis education](https://cedclinic.com/unlock-healing-potential-cannabis-audiobook/) resources. Document cannabis use patterns as you would any other substance—it’s clinical data that matters for patient safety.

💬 Join the Conversation

Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan)

Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/)

Have thoughts on this? Share it:

[𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20New%20ADAI%20Research%3A%20Cannabis-Related%20Problems%2C%20Adverse%20Events%2C%20Clinical%20Experienc...%20%40drcaplan&url=https%3A//adai.uw.edu/new-adai-research-cannabis-related-problems-adverse-events-clinical-experiences-and-barriers-to-intervening-for-health-care-providers-in-wa-state/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//adai.uw.edu/new-adai-research-cannabis-related-problems-adverse-events-clinical-experiences-and-barriers-to-intervening-for-health-care-providers-in-wa-state/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20New%20ADAI%20Research%3A%20Cannabis-Related%20Problems%2C%20Adverse%20Events%2C%20Clinical%20Experienc...%20--%20via%20%40drcaplan.bsky.social%20https%3A//adai.uw.edu/new-adai-research-cannabis-related-problems-adverse-events-clinical-experiences-and-barriers-to-intervening-for-health-care-providers-in-wa-state/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/)

📰 Source: [https://adai.uw.edu/new-adai-research-cannabis-related-problems-adverse-events-clinical-experiences-and-barriers-to-intervening-for-health-care-providers-in-wa-state/](https://adai.uw.edu/new-adai-research-cannabis-related-problems-adverse-events-clinical-experiences-and-barriers-to-intervening-for-health-care-providers-in-wa-state/)

Table of Contents

- [FAQ](#FAQ)[What is the clinical relevance rating for this cannabis news?](#What_is_the_clinical_relevance_rating_for_this_cannabis_news)
- [What specific areas of cannabis healthcare does this news cover?](#What_specific_areas_of_cannabis_healthcare_does_this_news_cover)
- [Why is provider training in cannabis medicine important?](#Why_is_provider_training_in_cannabis_medicine_important)
- [What should healthcare systems consider regarding cannabis use disorder?](#What_should_healthcare_systems_consider_regarding_cannabis_use_disorder)
- [How does this news impact clinical practice?](#How_does_this_news_impact_clinical_practice)
- [Related](#Related)

## FAQ

#### What is the clinical relevance rating for this cannabis news?

This article has been assigned CED Clinical Relevance #70, indicating “Notable Clinical Interest.” This rating suggests the content contains emerging findings or policy developments that healthcare providers should monitor closely.

#### What specific areas of cannabis healthcare does this news cover?

The article focuses on provider training, [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/), clinical education, and healthcare systems. These tags indicate the news addresses multiple aspects of cannabis-related healthcare delivery and professional development.

#### Why is provider training in cannabis medicine important?

Provider training is essential as [cannabis legalization](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/) expands and more patients seek cannabis-related healthcare services. Proper education ensures healthcare professionals can provide evidence-based guidance and identify potential cannabis use disorders.

#### What should healthcare systems consider regarding cannabis use disorder?

Healthcare systems need to develop protocols for screening, diagnosing, and treating cannabis use disorder as cannabis becomes more widely available. This includes training staff and implementing appropriate assessment tools and treatment pathways.

#### How does this news impact clinical practice?

This development represents emerging policy or educational initiatives that could influence how healthcare providers approach cannabis-related [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/). Clinicians should stay informed about these developments to provide current, evidence-based care.

{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “New ADAI Research: Cannabis-Related Problems, Adverse Events, Clinical Experiences …”, “url”: “https://adai.uw.edu/new-adai-research-cannabis-related-problems-adverse-events-clinical-experiences-and-barriers-to-intervening-for-health-care-providers-in-wa-state/”, “datePublished”: “2026-03-31T04:03:22Z”, “about”: “new adai research cannabis related problems”}

 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 

Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.

Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance

 [Leave a Message](https://cedclinic.com/contact/)
 [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
 [Medical Consulting](https://cedclinic.com/book/)
 [Cannabis Care](https://cedclinic.com/book/)
 

 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 

RELATED READING AT CED CLINIC

Continue exploring the evidence

[Cannabis-related health problems: WA clinical snapshot](https://cedclinic.com/cannabis-related-adverse-events-wa-snapshot/)

A detailed clinical snapshot of cannabis-related health problems in Washington State, providing context for provider experiences and patient care challenges.

[Read the WA Clinical Snapshot](https://cedclinic.com/cannabis-related-adverse-events-wa-snapshot/)

[CBD for Calm: How to Use It in Real Life (Timing, Format & What to Exp](https://cedclinic.com/cbd-dosing-anxiety-treatment-how-to-use-cbd-for-calm/)

Learn practical guidance on using CBD for calming effects, complementing clinical education on cannabis-related care.

[Explore CBD Usage Tips](https://cedclinic.com/cbd-dosing-anxiety-treatment-how-to-use-cbd-for-calm/)

[Common cannabis myths debunked: r/ukmedicalcannabis – Reddit](https://cedclinic.com/cannabis-misinformation-impact-clinical-decisions/)

Debunking common myths about cannabis to support evidence-based clinical education and informed patient discussions.

[Discover Cannabis Facts](https://cedclinic.com/cannabis-misinformation-impact-clinical-decisions/)

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).